Rheumatology

COVID-19

Questions discussed in this category

What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?

CDC Healthcare Guidance CDC Isolation and Work Restriction Guidance CDC Immunocompromised Guidance

1 Answer available

Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?

2 Answers available

How do you approach Covid vaccine counseling in patients with rheumatic disease and history of pericarditis/serositis?

1 Answer available

What is the difference between Multisystem Inflammatory Syndrome in Adults (MIS-A) and MAS/HLH?

1 Answer available

Do you recommend using IL-1/IL-6 inhibitors in COVID-19 multisystem inflammatory syndrome in adults (MIS-A)?

1 Answer available

Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

1 Answer available

Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?

2 Answers available

Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?

1 Answer available

How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?

Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?

2 Answers available

What are your recommendations regarding methotrexate usage in patients with persistent chest CT changes post COVID pneumonia?

Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?

2 Answers available

Do you recommend COVID vaccination in patients with antiphospholipid antibody positivity or other prothrombotic states not on anti-coagulation?

1 Answer available

How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?

1 Answer available

In which patients with autoimmune or inflammatory conditions are you recommending a 3rd dose of the mRNA COVID vaccine?

2 Answers available

How would you advise patients with known stable autoimmune thrombocytopenia regarding the Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine?

1 Answer available

How do you advise patients who had autoimmune diseases "triggered" by COVID infections on getting COVID vaccination?

E.g., inflammatory polyarthritis or inflammatory myopathy with onset within 2 weeks of documented COVID infection

1 Answer available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

1 Answer available

When would you recommended restarting biologic medications in an active RA patient after treatment with monoclonal antibodies, convalescent plasma or antiviral medications for a COVID-19 infection?

1 Answer available

Are you recommending tocilizumab for any COVID-19 patients?

Current guidelines do not support its use, but the EMPACTA trial suggests it may be effective in a subpopulation of patients.

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

Is there an increased risk of COVID-19 in patients on immunosuppressants?

1 Answer available

In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?

Acknowledging that there is no time for good trials yet in this setting

1 Answer available

Is your approach to managing immune related adverse events altered at all in light of COVID-19?

2 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Lancet Oncol., 2020 Mar 03

Risk of COVID-19 for patients with cancer.

Lancet, 2020 Feb 07

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

N Engl J Med, 2020 Apr 29

Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.

Rheumatol Int, 2020 Sep 18

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

N Engl J Med, 2020 Dec 10

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.

N Engl J Med, 2020 Dec 17

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.

Lancet Rheumatol, 2021 Apr 06

Incident systemic rheumatic disease following COVID-19.

N Engl J Med, 2020 Nov 20

Covid-19-Associated Myopathy Caused by Type I Interferonopathy.

Blood,

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

Arthritis Rheumatol, 2021 May 24

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.

N Engl J Med, 2021 Aug 04

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.

Semin Hematol,

Epidemiology and risk factors for venous thrombosis.

BMJ Open, 2019 May 05

Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.

Rheumatol Int, 2021 Jan 29

Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.

Thromb Res, 2021 Jun 25

Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.

ACR Open Rheumatol, 2021 Aug 25

Performance of Cytokine Storm Syndrome Scoring Systems in Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children.

Rheumatology

COVID-19

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology